Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alirocumab Phase 2 in Heterozygous Familial Hypercholesterolemia
NCT01266876Phase 2Completed
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Jan 2011
- Primary completion
- Nov 2011
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 2 trial of alirocumab in heterozygous familial hypercholesterolemia (HeFH), sponsored by Regeneron Pharmaceuticals. Started Jan 2011; status: completed.
02
Drugs
alirocumab
03
Conditions
heterozygous familial hypercholesterolemia (HeFH)
Beyond the preview
Go deeper on NCT01266876.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01266876.